The PCF TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award supports large-scale, multi-institutional team science investigations specifically targeting metastatic, lethal prostate cancer. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world, with an emphasis on cross-disciplinary collaboration. The award is among the largest in oncology private funding, aimed at delivering transformative therapy breakthroughs. Applications proceed through a three-stage process: Letter of Intent, full application (by invitation), and interview.
Eligibility Criteria:
- Teams of at least five investigators from non-profit academic research centers; must include at least two young investigators with doctoral degrees
- International applicants welcome; no geographic restrictions
- Large-scale research projects concerning metastatic, lethal prostate cancer over a duration of 3 to 5 years
- Clinical trial direct costs are not allowed; correlative research supporting high-impact clinical trials is encouraged
- Cross-disciplinary, diverse, and inclusive teams are prioritized
- Must be currently unfunded for the proposed research
Funding Details:
- PCF will fund 2–3 awards at $5–$10 million USD per award over 3 to 5 years
- Up to 10% indirect costs permitted
- Flexible use of funds to advance team science goals
Deadline:
- LOI submission deadline: March 16, 2026
- Submit LOI to pcftactical@pcf.org; see RFA for form instructions
- Full application by invitation only following LOI review
Where to Go for Further Information: